CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 5,500 enrolled
Drug / intervention
ROME IV Criteriaother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05340400
NCT05340400N/ACompleted
CompareCT.gov

The Prevalence and Risk Factors of Irritable Bowel Syndrome Among Adults: A Multi-Centre Cross-sectional Study.

University of Aleppo·observational·Posted Apr 22, 2022·Updated Jun 14, 2022

In Brief

An observational study evaluating ROME IV Criteria for Irritable Bowel Syndrome and Colonic Diseases, Functional. Completed, enrolled 5,500 participants across 2 sites.

Detailed Summary

This is a multicenter cross-sectional study on the prevalence of Irritable Bowel Syndrome and the risk factors associated with it. The Rome IV criteria is used for diagnosing IBS. A questionnaire-guided interview will be applied to all subjects.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsIrritable Bowel Syndrome, Colonic Diseases, Functional
CountriesSyria
Collaborators--

Timeline

N/ACompletedFinished
2023202420252026
First PostedApr 22, 2022
Enrollment StartApr 25, 2022
Primary CompletionMay 25, 2022
Study CompletionJun 10, 2022
TodayJul 2, 2026
Enrollment to primary: 1 monthPosted 4.2 years ago

Interventions

ROME IV Criteriaother

Collaborators will use Rome IV criteria for diagnosing IBS by the presence of the abdominal pain at least once a week in the last 3 months, in addition to at least two of the following: abdominal pain related to defecation, change in stool frequency, or shape.